Somewhat Favorable Press Coverage Somewhat Unlikely to Impact ChemoCentryx (CCXI) Share Price
News articles about ChemoCentryx (NASDAQ:CCXI) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. ChemoCentryx earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.8405319858665 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- Zacks Investment Research Lowers ChemoCentryx, Inc. (CCXI) to Hold (americanbankingnews.com)
- ChemoCentryx, Inc. (CCXI) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
- ChemoCentryx, Inc. (CCXI) Downgraded by ValuEngine (americanbankingnews.com)
- Critical Survey: ChemoCentryx (CCXI) vs. Cardiome Pharma Corporation (CRME) (americanbankingnews.com)
- ChemoCentryx, Inc. (CCXI) Issues Quarterly Earnings Results (americanbankingnews.com)
ChemoCentryx (NASDAQ:CCXI) traded up $0.08 during trading on Monday, reaching $7.49. The company had a trading volume of 59,000 shares, compared to its average volume of 141,167. ChemoCentryx has a 1 year low of $6.13 and a 1 year high of $10.80.
ChemoCentryx (NASDAQ:CCXI) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. analysts expect that ChemoCentryx will post -0.67 earnings per share for the current year.
A number of brokerages have recently weighed in on CCXI. Cowen and Company restated a “hold” rating on shares of ChemoCentryx in a research report on Tuesday, August 8th. Zacks Investment Research upgraded ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Monday, July 17th. BidaskClub cut ChemoCentryx from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 10th. Finally, ValuEngine cut ChemoCentryx from a “hold” rating to a “sell” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. ChemoCentryx has a consensus rating of “Hold” and an average price target of $8.25.
ChemoCentryx Company Profile
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Receive News & Stock Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related stocks with our FREE daily email newsletter.